Vertex Pharmaceuticals announced that Paul Negulescu, Ph.D., Senior Vice President, has been awarded the 2025 Canada Gairdner International Award. The award recognizes his pioneering research into the cellular and molecular mechanisms underlying cystic fibrosis (CF), which led to the development of transformative drug therapies.
Dr. Negulescu shares the award with Michael J. Welsh, M.D., from the University of Iowa. This honor highlights his outstanding vision and leadership in discovering the first protein folding corrector medicines that treat the underlying cause of CF, fundamentally changing the course of the disease.
Vertex's five approved CF medicines, including a triple combination therapy, have the potential to treat over 90% of people with CF with more than 300 different mutations. This prestigious award underscores Vertex's scientific excellence and its profound impact on the lives of CF patients globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.